I propose to take Questions Nos. 595 and 649 together.
The HSE proposes to introduce a formal returns arrangement with suppliers of High Tech Medicines in cases where a community pharmacy no longer has a requirement for particular medicine previously delivered to that pharmacy location. Such a returns arrangement will have to comply with relevant legislative and regulatory requirements. The HSE is also developing an electronic authorisation (e-authorisation) module in conjunction with prescribers in hospitals to improve the efficiency of the Scheme. Rheumatology is the initial clinical programme involved.
In relation to expenditure on High Tech Drugs, I wish to advise that this information is being collated by the HSE and will be forwarded to the Deputy as soon as it is available.